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ABSTRACT 
Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are a major 
development in the prevention of cardiovascular disease (CVD) and is one of the most 
significant discoveries since the development of statin therapy. Administration of two human 
monoclonal antibodies to PCSK9 (alirocumab and evolocumab) can significantly reduce LDL-
c concentrations thus improving lipid management. Accordingly, guidelines on the specific 
indications for alirocumab and evolocumab usage have been released. This multi-centre study 
aimed to estimate the proportion of patients treated for an acute myocardial infarction who 
could be considered for PCSK9 inhibitors under current National Institute for Health and Care 
Excellence (NICE) lipid targets criteria.  
Methods: The records of 596 patients in two large hospitals in Liverpool, UK were analysed. 
Information was collected on lipid profiles during and after admission, lipid-lowering therapy 
and previous CVD.  
Results: At least 2.2 % of patients were eligible for PCSK9 inhibitors post-MI under current 
NICE guidance. Additionally, 29 % of patients failed to achieve LDL-c concentrations < 2.0 
mmol/L despite maximum statin therapy, and failed to meet eligibility for PCSK9 inhibitors as 
per NICE criteria. This cohort represents a group of patients “in limbo’, in which statin therapy 
alone is not sufficient to reduce LDL-c. 
Conclusions: PCSK9 inhibitors are expensive and so their use must be highly selective. At 
present, in a real world setting with ezetimibe under-prescribing, ~2% of patients are eligible 
and a further 30% are deprived of benefit and improved outcomes by lack of optimisation 
and/or potential use of pcsk9 inhibitors.   
Abstract word count: 274 words 
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INTRODUCTION 
There is strong and consistent evidence from genetic studies, prospective epidemiologic cohort 
studies and randomised trials that a log-linear relationship exists between low-density 
lipoprotein cholesterol (LDL-c) concentrations and the risk of cardiovascular disease (CVD).1 
Statin therapy is established as first-line management for lowering LDL-c and significantly 
reduces the incidence of cardiovascular mortality, with more intense reductions in LDL-c 
resulting in additional cardioprotective benefits. It has been reported by Baigent et al, 2010 that 
for every 1 mmol/L reduction in LDL-c, there are significant reductions in all-cause mortality 
(12%), myocardial infarction and coronary disease (23%), and fatal or non-fatal strokes (17%).2 
Statins are generally considered safe and well tolerated but there are large cohorts of patients 
who are intolerant of the doses used to reduce LDL-c.3 The discontinuation of statin therapy 
after commencement is high and has been shown to be nearly 60% in the two-year period 
following an acute coronary syndrome (ACS) 4. The majority of statin intolerance is attributed 
to muscle-related adverse events but the size of this effect does not explain the level of non-
adherence to therapy.3 Intolerant patients experience myocardial infarctions up to 40% more 
frequently than patients adherent to high-intensity statin therapy (80mg atorvastatin or 20mg 
rosuvastatin)5. Non-adherence is complex and can include the fear of adverse effects, drug 
intolerance, poor follow-up by healthcare providers, and a lack of education or perception of 
benefits.6 Above all, patients who fail to sufficiently reduce their LDL-c remain at risk of 
hyperlipidaemia as mentioned above and thus require consideration for alternative therapies.  
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are a promising therapeutic 
option for patients with either intolerance or poor response to high intensity statin therapy 
including after optimisation with ezetimibe. Two human monoclonal antibodies to PCSK9 
(alirocumab and evolocumab) are currently licenced and have been shown to significantly 
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reduce LDL-c concentrations (average reduction of 3.15 mmol/L to 1.3 mmol/L), when used 
alone or in conjunction with maximum tolerated statin therapy (defined as the maximum 
licensed or tolerated dose required to achieve a reduction in LDL-c greater than 50% from 
baseline).7,8 FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition 
in Patients With Elevated Risk) trials demonstrated a  reduction in LDL-c when evolocumab 
was added to statin therapy.9 In this study, the addition of evolocumab to statin therapy 
significantly reduced the risk of cardiovascular events, myocardial infarction (MI) and stroke, 
reducing the risk of death by approximately 15%.9 Importantly, evolocumab caused no adverse 
effects as discontinuation rates were similar between treatment and placebo groups (both 
approximately 5% per year).10,11 
Alirocumab and evolocumab are now recommended as a treatment option for primary 
hypercholesterolemia by the National Institute for Health and Care Excellence (NICE) in 
patients identified as ‘high risk’ (in whom LDL-c > 4 mmol/L) or ‘very-high risk’ (in whom 
LDL-c > 3.5 mmol/L) of further cardiovascular events (Table 1), despite maximal tolerated 
lipid-lowering therapy.12,13 The European Society of Cardiology/European Atherosclerosis 
Society (ESC/EAS) suggest that alirocumab and evolocumab should be considered in patients 
with clinical atherosclerotic cardiovascular disease (ASCVD) and an LDL-c > 3.6 mmol/L, 
despite maximally tolerated statin therapy (with or without ezetimibe), statin intolerance, or  
LDL-c values  > 2.6 if additional indices of risk severity are present (e.g. diabetes with organ 
damage, repeated ACS, and ischaemic stroke).14,15–18 Data documenting the number of patients 
for whom alirocumab and evolocumab are an option under current scientific society guidance 
remains sparse. In this study, we aimed to estimate the proportion of patients following an MI 
in the real world setting who could be considered for alirocumab and evolocumab therapy 
based on lipid levels from current NICE guidance. 
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Without CVD With CVD 
 
 ‘High risk’ of CVD (history of 
ACS, coronary or other arterial 
revascularisation procedures; 
coronary heart disease; 
ischaemic stroke; peripheral 
arterial disease). 
‘Very-high risk’ of CVD 
(recurrent cardiovascular 
events or cardiovascular events 
in more than one vascular bed 
(poly-vascular disease) 
Not recommended at 
any LDL-c 
concentration 
Recommended only if LDL-c 
concentration is persistently ≥ 
4.0 mmol/L 
Recommended only if LDL-c 
concentration is persistently ≥ 
3.5 mmol/L 
 
Table 1. LDL-c thresholds for primary non-familial hypercholesterolemia or mixed 
hyperlipidaemiaintenis above which evolocumab is recommended (NICE).12,13 
 
METHODS 
The aim of this study was to understand lipid management in patients following an acute MI 
in a UK real world setting post CG 18119 and to estimate the proportion of patients who may 
be considered for therapy with PCSK9 inhibitors in the context of current NICE crtieria.19  The 
primary outcome was to ascertain the proportion of patients who are likely to satisfy the 
eligibility criteria for PCSK9 inhibitors post-MI using NICE lipid criteria. Secondary outcomes 
included the proportion of patient’s post-MI satisfying the lipid-lowering targets stated within 
NICE, and an estimation of the proportion of patients failing to meet eligibility for PCSK9 
inhibitors that require escalation of lipid-lowering therapy despite receiving the maximum 
tolerated statin therapy (i.e Atorvastatin 40-80 mg or Rosuvastatin 20-40 mg).  
Electronic clinical records of all patients admitted with ST-elevation MI (STEMI) or non-ST 
elevation MI (NSTEMI) to the Cardiology Departments at two large university teaching 
hospitals in Merseyside, UK (Aintree University Hospital, Liverpool, UK; Whiston Hospital, 
Prescot, UK) between 1st March 2015 and the 31st October 2015 were analysed. Data for each 
patient included: patient demographics, date of admission, admission lipid profiles (fasting or 
non-fasting), lipid lowering medications on admission (including dose), lipid lowering 
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medications at discharge, date of follow-up, lipid profile and history of CVD (to classify 
patients as ‘high risk’ or ‘very-high risk’ of future cardiovascular events). Variations in lipid 
and lipoprotein levels after acute MI manifest within 24 to 48 h following the onset of chest 
pain (termed the acute phase response). In situations where LDL-c values were not available, 
but total cholesterol and High-Density Lipoproteins (HDL) were recorded, LDL-c values were 
calculated using the externally validated formula: LDL-c = ¾ (TC – HDL-c).20 Patients were 
excluded from analysis if the post-intervention lipid profiles were not recorded or unavailable. 
In circumstances where multiple post-intervention (high-intensity statin therapy) lipid profiles 
were measured, the value closest to three months post-admission was used for analysis, in-line 
with NICE recommendations relating to the timeliness of high-intensity statin follow-up to 
monitor treatment efficacy.19 
According to NICE guidelines, ‘high risk’ patients (Table 1) are eligible for PCSK9 inhibitor 
therapy if LDL-c is persistently above 4 mmol/L, despite maximal tolerated lipid-lowering 
therapy. Similarly, ‘very-high risk’ patients (Table 1) are eligible for therapy if LDL-c is 
persistently above 3.5 mmol/L. Within this study, if a patient was identified with an LDL-C > 
4 mmol/L in ‘high risk’ patients (or > 3.5 mmol/L in ‘very-high risk’ patients) on two separate 
occasions (at least 3 months apart) whilst adhering to maximum tolerated statin therapy, they 
were classified as ‘eligible’ for treatment with PCSK9 inhibitors.  
Following an MI, patients that achieved at least a 40% reduction of non-HDL-c were defined 
as patient’s post-MI meeting lipid-lowering targets from high-intensity statin therapy. The 
proportion of patients failing to achieve this reduction despite maximum tolerated statin 
therapy, who did not meet the eligibility criteria for PCSK9 inhibitor treatment were classified 
as ‘requiring escalation of lipid-lowering therapy’.  
 
 
9 
 
RESULTS 
Between the 1st March 2015 and the 31st October 2015, 596 patients across both sites were 
admitted with acute MI. Of these patients, 366 were male (61.4%), with an average age of 69.3 
years (SD 12.6), and 230 were female (38.6%), with an average age of 74.2 years (SD 12.9) 
(Table 2). 
 n (%) 
Patient demographics 
Patient number 596 
Average age (years) male/female 69.3 / 74.2 
Male  366 (61.4) 
Female 230 (38.6) 
Lipid-lowering therapy at discharge 
Atorvastatin (80mg)  500 (83.89) 
Atorvastatin (10mg) 1 (0.17) 
Atorvastatin (20mg) 3 (0.50) 
Atorvastatin (40mg)  3 (0.50) 
Simvastatin (20mg)  3 (0.50) 
Ezetimibe (10 mg)  3 (0.50) 
No therapy 83 (13.93) 
Lipid values recorded at follow-up 
Data available  373 (62.58) 
Missing data  223 (37.42) 
Table 2. Patient demographics and lipid lowering therapies at hospital discharge 
following an ACS. 
 
The majority of patients (n=500, 84%) were discharged on atorvastatin 80mg daily and a 
further 10 patients (2%) treated with a lower dose or alternative statin (Table 2). Nearly 15% 
of patients (n = 84; 13.94%) were discharged without any form of lipid lowering therapy. The 
majority of these patients were recorded as allergic (n = 25) or intolerant (n= 56) to statin 
therapy. Of the 500 patients discharged on atorvastatin 80 mg daily, 323 had at least two LDL-
c measurements taken at least 3 months apart (Table 3). Of these, 204 patients had full 
cardiovascular history data available. We identified 173 patients at ‘high risk’ of future 
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cardiovascular events (defined as having a history of ACS) and 31 at ‘very-high risk’ (defined 
as having a history of recurrent cardiovascular events or cardiovascular events in more than 
one vascular bed). A large number of the patients discharged on atorvastatin (n=119) had no 
cardiovascular history, but by the nature of their admission for ACS, were  classified as ‘high 
risk’ for future cardiovascular events under NICE guidelines (Tables 4-6).19 
 n (%) 
Lipid-lowering therapy on admission 
No statin (%) 127 (25.4) 
Atorvastatin (80mg)  51 (10.2) 
Atorvastatin (10mg)  9 (1.8) 
Atorvastatin (20mg)  11 (2.2) 
Atorvastatin (40mg)  39 (7.8) 
Rosuvastatin (10mg)  2 (0.4) 
Rosuvastatin (20mg)  1 (0.2) 
Rosuvastatin (40mg)  1 (0.2) 
Simvastatin (10mg)  3 (0.6) 
Simvastatin (20mg)  19 (3.8) 
Simvastatin (40mg)  21 (4.2) 
Pravastatin (10mg)  1 (0.2) 
Pravastatin (20mg)  1 (0.2) 
Ezetimibe (10mg)  2 (0.4) 
Missing data  212 (42.4) 
Previous cardiovascular events 
Yes (‘very high-risk’)  51 (10.2) 
No (‘high-risk’)  237 (32.8) 
Unknown  212 (57.0) 
Post-admission lipid profile measured (at least 2 values separated by at 
least 3 months) 
Yes  323 (64.6) 
No  177 (35.4) 
Table 3. Lipid lowering therapy, Lipid data availability and clinical risk status of patients 
admitted with a diagnosis of ACS (n = 500). 
 
Of the 173 patients identified as high risk for future cardiovascular events, 127 (73.41%) had 
LDL-c < 2 mmol/L and 44 (25.43%) had LDL-c of 2–4 mmol/L. Two patients had LDL-c 
levels persistently > 4 mmol/L despite maximal statin therapy (1.16%) (Table 4, Figure 1). Of 
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the 31 patients identified as ‘very-high risk’ for future cardiovascular events, 14 had LDL-c < 
2 mmol/L (45.16%) and 13 (41.94%) had LDL-c concentrations of 2–3.5 mmol/L. Four 
patients had LDL-c persistently > 3.5 mmol/L (12.90%) (Table 5; Figure 1). Of the 119 patients 
with no cardiovascular data available (and classified as ‘high-risk’ on the grounds of their 
admission for ACS), 91 had LDL-c < 2 mmol/L (76.47%) and 27 (22.69%) had LDL-c ranging 
from 2-4 mmol/L. A single patient had LDL-c levels persistently above 4.0 mmol/L (0.84%) 
(Table 6, Figure 1). 
Lipid management in high-risk 
patients post-MI  
n LDL-c < 2 
mmol/L 
LDL-c 2 – 4 
mmol/L 
LDL-c > 4 
mmol/L 
High risk (defined as history of ACS, 
coronary or other arterial 
revascularisation procedures; coronary 
heart disease; ischaemic stroke; 
peripheral arterial disease) (%) 
 
173 
 
127 (73.41) 
 
44 (25.43) 
 
2 (1.16) 
Table 4. Lipid management in ‘high risk’ patients as defined in NICE guidelines. 
 
Lipid management in very-high risk 
patients post-MI  
n LDL-c < 
2 
mmol/L 
LDL-c 2 – 
3.5 mmol/L 
LDL-c > 3.5 
mmol/L 
Very-high risk (defined as recurrent 
cardiovascular events or cardiovascular 
events in more than 1 vascular bed 
(poly-vascular disease) (%) 
 
31 
 
14 
(45.16) 
 
13 (41.94) 
 
4 (12.90) 
Table 5. Lipid management in very-high risk patient as defined in NICE guidelines.  
 
Lipid management in post-MI 
patients in whom risk level is 
unknown  
n LDL < 2 
mmol/L 
LDL-c 2 – 4 
mmol/L 
LDL-c > 4 
mmol/L 
At least high-risk (due to experiencing 
MI), but unknown cardiovascular 
history. (%) 
119 91 (76.47) 27 (22.69) 1 (0.84) 
Table 6. Lipid management in patients in which the risk level was unknown.  
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Of the patients admitted without any form of lipid lowering therapy and subsequently 
discharged on atorvastatin 80 mg, (n=59), the average reduction in non-HDL cholesterol was 
33.4% (SD 22.2%). Nearly 50% of participants failed to achieve the recommended reduction 
following the initiation of atorvastatin 80mg therapy post-MI (n = 28, 47.5%) (Table 7). 
 No statin 
therapy at 
admission 
Low or medium 
dose statin 
therapy at 
admission 
Atorvastatin 
(80mg) at 
admission 
Patient demographics 
Patient number 59 64 23 
Average age (years) 70.45 (SD 11.41) 69.31 (SD 11.01) 72.65 (SD 9.99) 
Male (%) 23 (38.98) 25 (42.37) 18 (78.26) 
Female (%) 36 (61.02) 34 (57.63) 5 (21.74) 
 
Admission 
Mean non-HDL-c (mmol/L) 3.76 (SD 0.98) 3.01 (SD 1.07) 3.1 (SD 1.29) 
Mean LDL-c (mmol/L) 3.04 (SD 0.96) 2.37 (SD 0.98) 2.20 (SD 0.82) 
 
Follow-up 
Average time to follow-up 
(months) 
9.99 (SD 5.65) 9.05 (5.40) 12.15 (6.48) 
Mean non-HDL-c (mmol/L) 2.41 (SD 0.76) 2.23 (SD 0.71) 3.21 (SD 1.06) 
Mean reduction in non-HDL-
c (mmol/L) % 
33.40 (SD 22.2) 22.73 (SD 19.04) -10.01 (SD 
27.69) 
Number achieving >40% 
reduction in non-HDL-c (%) 
31 (52.54) 14 (21.89) 1 (4.35) 
Mean LDL-c (mmol/L) 1.78 (SD 0.71) 1.62 (SD 0.60) 2.39 (SD 0.88) 
LDL-c < 2 mmol/L [No of 
participants] (%) 
42 (71.19) 49 (76.56) 8 (34.78) 
LDL-c 2–4 mmol/L [No of 
participants] (%) 
17 (28.8) 13 (20.31) 14 (60.87) 
LDL-c > 4 mmol/L [No of 
participants] (%) 
0 (0) 1 (1.56) 1 (4.35) 
Table 7. Lipid profiles at admission and follow-up in patients discharged on 80mg 
atorvastatin for which admission and follow-up data was available.  
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DISCUSSION 
NICE has based its recommendations for PCSK9 inhibitor administration on the analysis of 
cost-effectiveness in the UK, the observed reduction of LDL-c in PCSK9 inhibitor trials, 
modelled risk reductions with therapy, and derivation of the corresponding ICERs expressed 
in cost per QALY. In this multi-centre study, at least 2.17% of patients would be deemed 
eligible for PCSK9 inhibitors post-MI according to NICE lipid criteria. These included 1.24% 
of very-high risk patients having LDL-c persistently above 3.5 mmol/L and 0.93% of high-risk 
patients having LDL-c above 4.0 mmol/L despite maximum statin therapy. We found that 
29.1% of patients failed to have their LDL-c controlled to below 2 mmol/L but did not reach 
the NICE benchmark values for PCSK9 inhibitor eligibility, despite receiving statin therapy. 
This sizeable cohort represents a group of “in limbo’ patients in which statin therapy fails to 
achieve sufficient LDL-c reductions, but LDL-c is not sufficiently elevated under NICE criteria 
to warrant PCSK9 inhibitor treatment.  This group of patients would invariably benefit from 
optimisation of their lipid therapy by addition of Ezetimibe if tolerated or the direct addition of 
PCSK9 inhibitors for which at present they remain ineligible. Although not included in the 
NICE criteria, the question of how post-MI patients who are intolerant or allergic to statin 
therapy should be managed remains uncharacterised. Such patients represent a sizeable 
proportion of our study cohort (13.6%), that remain at a high-risk of suffering adverse 
outcomes relating to hyperlipidaemia.  
Zamora et al, 2018 investigated which patients would be eligible for PCSK9 inhibitors using 
scientific society guidance including estimating eligibility against NICE guidance for the 
secondary prevention of CVD.16 It was found that for optimised patients (defined as lipid 
lowering of > 50% and an adherence of > 80%), 0.7% of patients were eligible. Additionally, 
7.5% of patients not receiving lipid-lowering therapy were eligible under NICE guidance 16,19 
Upon comparison to the criteria of scientific societies, NICE was identified as the most 
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stringent. For example, in accordance with the European Society of Cardiology / European 
Atherosclerosis Society (ESC/EAS) guidance in the same patient cohort, 5.1% and 16.2% of 
patients, respectively, were deemed eligible. This was dependent on the patients previously 
receiving optimal lipid-lowering therapy.14,16 
The clinical effectiveness of PCSK9 inhibitors is widely accepted and described as the most 
important risk-reducing therapy since the advent of statins 21,22. The major barrier to their 
widespread use is cost and availability. The US list price of Evolocumab is $14,000 a year, 
which would require a reduction of nearly 70% to $4124, to achieve a cost-effectiveness 
threshold of $100,000 per quality-adjusted life year (QALY) 23. In the UK, the list price of 
evolocumab is lower at £4,383 per annum, but the cost-effectiveness threshold is applied by 
NICE 24. Importantly, the effects of PCSK9 inhibitors on LDL-c and the associated reduction 
in cardiovascular risk is meaningless to patients unable to access this medication due to cost.  
Kazi et al.  25 applied the established Cardiovascular Disease Policy Model (CDPM) to project 
the clinical and economic consequences of PCSK9 inhibitors in addition to statins for the 
secondary prevention of CVD. They modelled the reduction in LDL-c levels as reported by 
short-term studies of PCSK9 inhibitors, and assumed that lowering LDL-c would reduce 
coronary heart disease to the same extent as reported in pooled data from large RCTs of statins: 
a relative risk of 0.76 per mmol/L reduction in LDL-c. They also assumed that PCSK9 
inhibitors would continue to be effective for the patient’s lifetime, at a cost of $14,350 per 
annum. It was projected that the use of PCSK9 inhibitors for 5 years in all US adults for whom 
they are indicated would total $592 billion in drug spending, offset against $28 billion in 
averted cardiovascular events 24. The published results suggest that the cost per QALY for 
PCSK9 inhibitors added to statins for the secondary prevention of CVD would be $316,000 
per QALY 21. Thus, the cost-effectiveness of PCSK9 inhibitors do not meet accepted 
benchmarks for good value at present.24  
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This study had a number of limitations. Firstly, of the 596 patients admitted over both sites, 
only 323 of the 500 patients discharged on atorvastatin had at least two LDL-c values measured 
at least 3 months apart (64.6%). Furthermore, of those discharged on atorvastatin, only 204 
patients (63.2%) had full data available on their previous cardiovascular events. This limited 
the ability to upgrade a patient from being classified as high risk for subsequent cardiovascular 
events, to being classified as very-high risk. This may have led to an underestimation of the 
patients eligible for PCSK9 inhibitor therapy under NICE criteria (Table 1).19 Secondly, no 
data was collected on the adherence to therapy; and as such, it is impossible to determine 
whether patients adhered to the lipid-lowering therapeutic regimen, which has the potential to 
exaggerate the number of patients eligible for PCSK9 inhibitor therapy. Thirdly, once patients 
were discharged from secondary care, the lipid management responsibility falls on the primary 
care physicians. This has the potential to impact both the long-term monitoring of the response 
to therapy and the educational needs of patients.  
To our knowledge, this is the first study to estimate the proportion of patients following ACS 
who are eligible for PCSK9 inhibitor therapy in accordance with NICE criteria. We importantly 
reveal a significant proportion of high-risk patients to whom PCSK9 inhibitors would be 
beneficial. This cohort of patients in which the response to maximum tolerated lipid-lowering 
therapy is inadequate by NICE aims (reduction in non-HDL-c > 40% following the introduction 
of high dose statin therapy), do not reach the NICE targets for PCSK9 inhibitor treatment. An 
issue therefore remains as to how patients these patients are managed. Until the costs of 
alirocumab and evolocumab are reduced by pharmaceutical companies and healthcare 
providers, their true benefits to the large groups of patients who would benefit from their 
administration are yet to be observed. Current studies show that combining statin therapy with 
ezetimibe can promote the dual inhibition of both cholesterol production and absorption. Until 
PCSK9 inhibitors become more readily available, using this combination to achieve lower 
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serum cholesterol levels and more optimised lipid levels in post-MI patients is likely to be the 
only option at the moment, with single agent ezetimibe and or possibly in combination with 
lower doses of statins to circumvent the problem of statin intolerance. 
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Figure legends 
Figure 1: Number of patients post MI as per patient risk group and their LDLc levels. The 
figures are derived from NICE guidance for patients who are eligible for PCSK9. Groups are 
divided to very high, high and unknown risk (but at least high due to MI). 
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Main messages of the article (Real world data show that post CG181 guidance): - 
 
- Most post MI patients (84%) are discharged on Atorvastatin 80 mg daily. 
- Approximately 50% of statin naive MI patients achieve a >40% reduction in non-HDL-c 
with Atorvastatin 80mg daily.   
- Approximately 30% of statin naïve MI patients prescribed Atorvastatin 80mg would have 
an LDL>2 mmol/L on follow up post MI.  
- Similarly, 30% of all post MI patients have an LDL>2 mmol/L on follow up but do not 
meet NICE lipid level criteria for pcsk9 prescription. 
- 15% of post MI patients are discharged on no statin therapy, being defined as allergic or 
intolerant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
24 
 
Remaining unanswered questions: 
 
- How should ‘’statin intolerant’’ patients be optimally managed? 
- How could the use of Ezetimibe be increased in the care of the post MI patient? 
- Should cardiac rehabilitation programs be more involved in addressing patient self-
management, appropriate prescribing and good lipid control in these high risk patients? 
 
